1. Characteristic 1: a method to treat the modulation, mediation or influence of estrogen receptor in the experimental subjects, which is characterized by the management of a compound subject selected from the formula group (1),R1 and R2 are independent: (I) Oh or r8313,(I) where to choose r8313 without considering h, halogen (CL, Br, I or F)；natural or natural amino acid (linked via OC (O) - o C (O) O- (an ester) o amino (via -C (O) -N- o -NC (O) - (an amide bandage)) ,R830404,-OR o -SR en donde R es -C (3DO) RC-C (3DO) ORC-C (3DO) SRC-C (3DO) N (RC)O polyethylene glycol, alternative or unsubstituted asphalt, alternative or unsubstituted acrylonitrile, alternative or unsubstituted asphalt, alternative or unsubstituted thyroid, alternative or unsubstituted isopropene, alternative or unsubstituted arilo, alternative or unsubstituted isopropene, alternative or unsubstituted； - S (= O) 83222；； rc21,-S (3DO) ORC-S (3DO) RC -S (3DO) ORC-P (3DO) RC-P (3DO) ORC-P (3DO) (ORC)-P (3DO) (RC) o -P (R) (ORC)Or oxygen and oxygen protection group (for Oh production in administration)The sulfur and sulfur protection group (for the production of SH or the production of disulfide in the government) or the nitrogen and nitrogen protection group (for the production of - NH - in the government) and RS1 can select hydrogen, polyethylene, alternative or unsubstituted tar separately, a. Substituted or unsubstituted beryllium, substituted or unsubstituted asphalt, substituted or unsubstituted carbohydrate, substituted or unsubstituted isopropene, substituted or unsubstituted arilo or substituted or unsubstituted isopropene, or two RC1 groups together to form substituted or unsubstituted heterocyclic；Or a pharmaceutically acceptable salt, a solution, a hydrate, a propha, a stereoisomer, a tautometer or nitrous oxide, plus a specific preparation consisting of mTOR inhibitors, CDK4 / 6 inhibitors, quinasa PI3 inhibitors, a taxonomic compound, Antiviral and antitumor antibiotics Claim 15: the m
